Is Cyclacel Pharmaceuticals Inc (CYCC) a Winner in the Biotechnology Industry?

The 39 rating InvestorsObserver gives to Cyclacel Pharmaceuticals Inc (CYCC) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 27 percent of stocks in the Biotechnology industry, CYCC’s 39 overall rating means the stock scores better than 39 percent of all stocks.

CYCC has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on CYCC!

See Full CYCC Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 39 means the stock is more attractive than 39 percent of stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cyclacel Pharmaceuticals Inc Stock Today?

Cyclacel Pharmaceuticals Inc (CYCC) stock is flat 0% while the S&P 500 is higher by 0.74% as of 3:59 PM on Wednesday, Mar 6. CYCC is unchanged $0.00 from the previous closing price of $2.37 on volume of 978 shares. Over the past year the S&P 500 is higher by 28.82% while CYCC is down -78.36%. CYCC lost -$29.70 per share the over the last 12 months. Click Here to get the full Stock Report for Cyclacel Pharmaceuticals Inc stock.